Revenue
2022
2023
2024
2025
Phathom Pharmaceuticals, Inc. (PHAT)
Price$8.90Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $175.1M | $55.3M | $682,000 | $0 | — | — | — | — |
| Gross profit | $152.5M | $47.3M | $515,000 | $0 | — | — | — | — |
| Gross margin | 87.09% | 85.57% | 75.51% | — | — | — | — | — |
| Research & development | $32.8M | $34.1M | $49.9M | $71.4M | $72.3M | $98.1M | $20.4M | $20,000 |
| Operating expenses | $312.5M | $324.7M | $167.8M | $172.4M | $135.1M | $125.7M | $106.2M | $1.2M |
| Operating income | −$160.0M | −$277.5M | −$167.3M | −$172.4M | −$135.1M | −$125.7M | −$106.2M | −$1.2M |
| Operating margin | −91.36% | −502.18% | −24,532.55% | — | — | — | — | — |
| EBITDA | −$159.4M | −$276.7M | −$166.7M | −$171.8M | −$134.6M | −$125.3M | −$106.2M | −$1.2M |
| EBITDA margin | −91.00% | −500.75% | −24,448.24% | — | — | — | — | — |
| Net income | −$221.2M | −$334.3M | −$201.6M | −$197.7M | −$143.9M | −$129.1M | −$255.1M | −$1.3M |
| Net profit margin | −126.35% | −605.09% | −29,558.94% | — | — | — | — | — |
| Basic EPSper basic share | -$3.03 | -$5.29 | -$3.93 | -$5.05 | -$3.89 | -$3.88 | -$22.45 | -$0.21 |
| Diluted EPSper diluted share | -$3.03 | -$5.29 | -$3.93 | -$5.05 | -$3.89 | -$3.88 | -$22.45 | -$0.21 |
Owners
Reported shareholders
15.57%of listed shares
Frazier Life Sciences Management, L.P.12.47M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Frazier Life Sciences Management, L.P. | 15.57%12.47M shares |
Medicxi Ventures Management (Jersey) Ltd | 9.32%7.46M shares |
Topper James N | ≈7.44%5.96M shares |
BlackRock, Inc. | 5.65%4.53M shares |
Invesco Ltd. | 5.03%4.03M shares |
Carlyle Group Inc. | 4.37%3.5M shares |
MILLENNIUM MANAGEMENT LLC | 4.22%3.38M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.32%2.66M shares |
GW&K Investment Management, LLC | 2.71%2.17M shares |
FRANKLIN RESOURCES INC | 2.46%1.97M shares |
NEA Management Company, LLC | 2.45%1.96M shares |
683 Capital Management, LLC | 2.31%1.85M shares |
GOLDMAN SACHS GROUP INC | 2.22%1.78M shares |
STATE STREET CORP | 1.98%1.59M shares |
Catalys Pacific, LLC | 1.87%1.49M shares |
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.83%1.46M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.64%1.32M shares |
WASATCH ADVISORS LP | 1.63%1.31M shares |
Nabulsi Azmi | ≈1.38%1.1M shares |
Ensign Peak Advisors, Inc | 1.31%1.05M shares |
Percentages use 80.07M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 3, 2025Form 4 | Breedlove Robert CharlesPrincipal Accounting Officer | SellCommon Stock | 524 | $13.51 | $7.1K | 47.4K |
| Sep 5, 2025Form 4 | Breedlove Robert CharlesPrincipal Accounting Officer | SellCommon Stock | 461 | $12.09 | $5.6K | 47.9K |
| Jul 16, 2025Form 4 | Breedlove Robert CharlesPrincipal Accounting Officer | SellCommon Stock | 1.7K | $8.36 | $14.1K | 48.4K |
| May 21, 2025Form 4 | Topper James NDirector | BuyCommon Stock · indirect | 3.8K | $3.86 | $14.6K | 59.4K |
| May 14, 2025Form 4 | Topper James NDirector | BuyCommon Stock · indirect | 6.3K | $3.32 | $20.9K | 55.6K |